Vaccines and Global Health: The Week in Review
29 April 2023 :: Issue 701
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
 :: Coronavirus [COVID-19] - WHO
 :: Organization Announcements
 :: Journal Watch
 :: Pre-Print Servers
Response to “Backsliding”

Global partners announce a new effort – “The Big Catch-up” – to vaccinate millions of children and restore immunization progress lost during the pandemic

Press release 24 April 2023

- The pandemic saw essential immunization levels decrease in over 100 countries, leading to rising outbreaks of measles, diphtheria, polio and yellow fever.
- ‘The Big Catch-up’ is an extended effort to lift vaccination levels among children to at least pre-pandemic levels and endeavours to exceed those.
- Led by a broad range of national and global health partners, The Big Catch-up also aims to ensure stronger primary health care services for essential immunization in the future.

Geneva/New York/Seattle, 24 April 2023 – The World Health Organization (WHO), UNICEF, Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation, along with Immunization Agenda 2030 and many other global and national health partners, are today joining forces to call for “The Big Catch-up”, a targeted global effort to boost vaccination among children following declines driven by the COVID-19 pandemic.

This effort aims to reverse the declines in childhood vaccination recorded in over 100 countries since the pandemic, due to overburdened health services, closed clinics, and disrupted imports and exports of vials, syringes and other medical supplies. Meanwhile, communities and families experienced lockdowns, restricting travel and access to services, and financial and human resources were limited along with access to health commodities, due to the emergency response. Ongoing challenges like conflicts, climate crises and vaccine hesitancy also contributed to the decline in coverage rates.

With over 25 million children missing at least one vaccination in 2021 alone, outbreaks of preventable diseases, including measles, diphtheria, polio and yellow fever are already becoming more prevalent and severe. The Big Catch-up aims to protect populations from vaccine-preventable outbreaks, save children’s lives and strengthen national health systems.

While calling on people and governments in every country to play their part in helping to catch up by reaching the children who missed out, The Big Catch-up will have a particular focus on the 20 countries where three quarters of the children who missed vaccinations in 2021 live*...

WHO Director-General Dr Tedros Adhanom Ghebreyesus said: "Millions of children and adolescents, particularly in lower-income countries, have missed out on life-saving vaccinations, while outbreaks of these deadly diseases have risen. WHO is supporting dozens of countries to restore immunization and other essential health services. Catching up is a top priority. No child should die of a vaccine-preventable disease."

“Routine vaccines are typically a child’s first entry into their health system and so children who miss out on their early vaccines are at added risk of being cut out of health care in the long run,” said UNICEF
Executive Director Catherine Russell. “The longer we wait to reach and vaccinate these children, the more vulnerable they become and the greater the risk of more deadly disease outbreaks. Countries, global partners and local communities must come together to strengthen services, build trust and save lives.”...

::::::

**Measles**

**South Sudan launches major push on measles vaccination**

- The *measles campaign aims to vaccinate more than 2.7 million children* against the highly infectious disease, and is integrated with efforts to deliver Vitamin A supplementation and deworming.
- Between January 2022 and 1 February 2023, health authorities in South Sudan reported an *outbreak of measles, with over 4,000 suspected cases and 46 deaths* across the country.
- The campaign will use a combination of fixed and outreach vaccination sites, with a focus on reaching under or unvaccinated children aged between 6-59 months in hard-to-reach areas.

Juba, 24 April 2023 – The Ministry of Health, South Sudan, in partnership with Gavi, the Vaccine Alliance, UNICEF, WHO and other key partners, has launched a nationwide measles vaccination campaign. The campaign aims to vaccinate more than 2.7 million children aged 6-59 months against the highly infectious disease.

The launch of the measles vaccination campaign highlights South Sudan's resilience in rolling out immunization campaigns despite competing health priorities including recovery from the COVID-19 pandemic...

::::::

**HPV**

**Immunisation partners outline ambitious plan to protect millions of girls in lower- and middle-income countries against cervical cancer**

- Over the next few years, Gavi, the Vaccine Alliance and partners will focus efforts to revitalise access to the human papillomavirus (HPV) vaccine to reach 86 million adolescent girls, rapidly recover and improve coverage, and help build sustainable vaccination programmes.
- Despite the availability of the HPV vaccine in the Gavi portfolio, the vaccine’s ability to prevent cervical cancer, and the number of introductions into routine immunisation programmes, *global HPV vaccination coverage for final dose stands at 12% – with supply constraints, demand challenges and pandemic-related school closures hampering and setting back progress in recent years*

Geneva, 27 April 2023 – Gavi, the Vaccine Alliance and partners have committed to reach 86 million adolescent girls with the human papillomavirus (HPV) vaccine by 2025, outlining an action plan following the Gavi Board’s approval of the revitalisation of the HPV programme.
Over the course of the next three years, the Vaccine Alliance – which includes country governments, the World Health Organization, UNICEF, the Bill & Melinda Gates Foundation, civil society and other key partners – will work with low- and middle-income countries to help even more adolescent girls access this life-saving vaccine. This revitalisation push will be on three fronts:

- **Introductions**: providing new funding and assistance to introduce the HPV vaccine into routine immunisation schedules;
- **Catch up and strengthen**: implementing multi-age cohort (MAC) vaccination to rapidly catch up and improve coverage; and
- **Integration**: promote sustainability through the integration of HPV vaccination into routine immunisation and primary health care.

In parallel, Gavi will also offer support to countries to optimise the 2022 WHO Strategic Advisory Group of Experts on Immunization (SAGE) one-dose recommendation, which now enables countries to opt for a single-dose schedule for the HPV vaccine. Country-led decision making to adopt and implement the new guidelines, as per country choice, will be critical.

Some of the countries that Gavi anticipates will receive support in the next 12 months include Bangladesh, Cambodia, Ethiopia, Indonesia1, Kenya, Nigeria, Togo and Zambia. Gavi will also continue to work with countries that have already introduced the vaccine to help improve coverage and other countries to plan for future introductions...

::::::

Vaccines in Fragile, Humanitarian Contexts

**Funding disbursed to boost vaccine access in humanitarian and fragile settings**

- **Over US$ 30 million** is being released through the Zero-Dose Immunization Programme (ZIP) to two international consortia, led by **International Rescue Committee (IRC) and World Vision**, to help immunise over 3 million unvaccinated children living in 11 African countries.
- The funding will enable international and local civil society organisations to complement public health service efforts by accessing communities not reached by government services, such as in cross-border settings and conflict zones, across the Horn of Africa and Sahel.

Geneva, 26 April 2023 – Millions of children living in some of the world’s hardest to reach communities are to get access to essential vaccines for the first time, thanks to funding from Gavi, the Vaccine Alliance’s **Zero-Dose Immunization Programme (ZIP).**

The push to reach ‘zero-dose’ children – those who have not received a single routine vaccine shot – is focused on two regions, the Horn of Africa and the Sahel and specifically in areas where children have traditionally been hard to reach through government programmes. **For the first time, the Gavi funding is being channeled through two international civil society organizations**, the International Rescue Committee (IRC) and World Vision (the Sahel) which will in turn build the local partnerships and tailored approaches suitable for their respective regions.

"With millions of children systemically missing out on routine vaccines every year, these targeted investments will help us reach some of the hardest to reach children," said Thabani Maphosa, Managing Director of Country Programmes Delivery at Gavi. "The Zero-Dose Immunization Programme..."
is taking on our toughest challenges, working with new partners and new innovations to access communities in humanitarian settings.”

The funding will support a number of projects and pilot programmes – and will also go towards the implementation of a learning agenda to identify and develop the best methods and practices to reach children living in fragile, conflict and cross-border settings...

::::::
::::::

Malaria

Gavi outlines plans to build sustainable supply of malaria vaccines
- Following successful pilots, 2023 will see countries start to prepare for the rollout of the world’s first malaria mass vaccinations; however, long-term supply and affordability remain a challenge.
- A new paper published today by Gavi outlines how the world can increase supply to meet demand within the next few years by growing the number of manufacturers and supporting scale-up through predictable demand.
- Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance: “It has taken the world more than 50 years to develop a malaria vaccine. Yet this year’s launch serves only as a reminder of what needs to happen now if we are to make malaria vaccines accessible to every child that needs them.”

Geneva, 25 April 2023 – The world’s first effective malaria vaccine is finally available, but supply must grow significantly to meet demand. With an estimated 40-60 million doses currently to be needed by 2026 alone, growing to 80-100 million doses of vaccines needed each year by 2030, Gavi, the Vaccine Alliance, today published a white paper outlining actions that must be taken by governments, vaccine manufacturers and health agencies to meet this goal...

::::::
::::::

Africa needs to vaccinate 33 million children to put progress back on track
Brazzaville, 20 April 2023 – An estimated 33 million children will need to be vaccinated in Africa between 2023 and 2025 to put the continent back on track to achieve the 2030 global immunization goals that include reducing morbidity and mortality from vaccine-preventable diseases, an analysis by World Health Organization (WHO) finds.

The unprecedented impact of the COVID-19 pandemic on routine immunization services has driven up the number of zero-dose and under-immunized children, rising by 16% between 2019 and 2021 and pushing the cumulative total (2019–2021) to around 33 million, which represents nearly half the global figure, according to estimates by WHO and UNICEF.

“The pandemic has seriously set back the region’s vaccination efforts and left millions of children vulnerable to vaccine-preventable diseases that can cause serious illness and even death,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “As countries strive to emerge from the long shadow of COVID-19, we cannot afford to lose further ground. Every effort must be made to ensure every child has access to essential vaccines.”
Without renewed political will and intensified efforts by governments, it is estimated that vaccination coverage in Africa will not return to pre-pandemic levels until 2027.

This year, African Vaccination Week and World Immunization Week, from 24–30 April, is being marked under the theme "The Big Catch-Up". This is a global push by WHO and partners to intensify efforts to reach children who missed vaccinations, as well as to restore and strengthen routine immunization programmes...

To urgently scale up coverage and protect children, WHO and partners are supporting 10 priority African countries—which are among the top 20 countries globally with the highest numbers of zero-dose children—to carry out catch-up routine vaccination campaigns.

African governments and healthcare workers made heroic efforts during an unprecedented public health emergency, vaccinating more people than ever before in history. But the ripples of this emergency response effort are still being felt. At the Vaccine Alliance we are intensifying our efforts to support countries to make up lost ground,“ said Aurelia Nguyen, Chief Programme and Strategy Officer for Gavi, the Vaccine Alliance...

Despite the disruptions, at least one third of African countries have sustained the target coverage of 90% or higher for the third dose of the diphtheria-tetanus-pertussis vaccine, and the third dose of the polio vaccine, over the past three years. However, only three countries have sustained this coverage for the second dose of the measles and yellow fever vaccines during the same period.

The region has also continued to step up the polio response. More than 30 million children were vaccinated against polio in Malawi, Mozambique, Tanzania, Zambia and Zimbabwe in 2022, following wild poliovirus type 1 cases being reported in Malawi and Mozambique.

“The ambition to ensure that every child has access to essential vaccines by 2030 is still within our reach if we act now,” said Dr Moeti. “It is time for us to renew our commitment to this ambition and work...

::::::

Featured Journal Content

Scientific Reports
https://www.nature.com/srep/articles?type=article
Article
A global analysis of the effectiveness of policy responses to COVID-19
Kwadwo Agyapon-Ntra & Patrick E. McSharry
volume 13, Article number: 5629 (2023) Open Access
Published: 06 April 2023
Abstract
Governments implemented many non-pharmaceutical interventions (NPIs) to suppress the spread of COVID-19 with varying results. In this paper, country-level daily time series from Our World in Data facilitates a global analysis of the propagation of the virus, policy responses and human mobility
patterns. High death counts and mortality ratios influence policy compliance levels. Evidence of long-term fatigue was found with compliance dropping from over 85% in the first half of 2020 to less than 40% at the start of 2021, driven by factors such as economic necessity and optimism coinciding with vaccine effectiveness. NPIs ranged from facial coverings to restrictions on mobility, and these are compared using an empirical assessment of their impact on the growth rate of case numbers. Masks are the most cost-effective NPI currently available, delivering four times more impact than school closures, and approximately double that of other mobility restrictions. Gathering restrictions were the second most effective. International travel controls and public information campaigns had negligible effects. Literacy rates and income support played key roles in maintaining compliance. A 10% increase in literacy rate was associated with a 3.2% increase in compliance, while income support of greater than half of previous earnings increased compliance by 4.8%.

Figure 6
From: A global analysis of the effectiveness of policy responses to COVID-19

Intellectual Property/IP

**Boom in COVID-19 Fighting Tech; China, USA, Republic of Korea, Germany, and UK Lead**

Innovators around the world have filed thousands of patent applications for new technologies to battle the COVID-19 pandemic, with the vast majority of the envisioned products related to therapies to help stricken patients, a new WIPO report shows.

Apr 20, 2023 [PR/2023/900](PR/2023/900)
Overall, China, USA, Republic of Korea, Germany and UK were the leading origins of the 7,758 patent applications filed between January 2020 and September 2022, according to the newly published “Patent Landscape Report: COVID-19-related vaccines and therapeutics.”

Among the patent applications, which are one measure of human innovative activity, some 4,787 were for therapeutics meant to help people already infected with the coronavirus that causes COVID-19 – including nearly 10 percent of the patents based on traditional medicine. Some 1,298 of the applications were for vaccine development.

The speed of innovation in this field has been built on a foundation of scientific research and R&D investment stretching over decades, which in turn, has been supported by the incentives provided by the global IP ecosystem.

This patent landscape report provides researchers, decision makers and other stakeholders with insights into how the patent system has adapted and responded to the challenges of the last two and a half years.

Other key findings include:
- China leads the origin of patent applications in both vaccines and therapeutics, followed by the United States, Germany and the Republic of Korea for vaccines, and the United States, Republic of Korea and India for therapeutics.
- Patent filings were almost evenly split between companies and research organizations: 52 percent and 42 percent, respectively, for vaccines, and 49 percent and 38 percent, respectively, for therapeutics.
- Antibodies are the fastest growing type of biologic therapeutics, accounting for about one-third of the patents filed in this category. Their newly developed virus-neutralizing form represents a new class of antivirals.
- About a quarter of the applications filed had more than one assignee, indicating collaborations among companies and research organization.

---

**PHEIC**

**Coronavirus [COVID-19] - WHO**

Public Health Emergency of International Concern (PHEIC)

https://www.who.int/emergencies/diseases/novel-coronavirus-2019

**Weekly Epidemiological and Operational updates**

Last update: 29 March 2023

**Confirmed cases**: 764,474,387

**Confirmed deaths**: 6,915,286

**Vaccine doses administered**: 13,342,550,736

**Weekly epidemiological update on COVID-19 - 27 April 2023**

**Overview**

Globally, nearly 2.8 million new cases and over 16,000 deaths were reported in the last 28 days (27 March to 23 April 2023), a decrease of 23% and 36%, respectively, compared to the previous 28 days (27 February to 26 March 2023). Contrary to the overall trend, increases in reported cases and deaths continued to be seen in the South-East Asia and Eastern Mediterranean regions and in several
individual countries elsewhere. As of 23 April 2023, over 764 million confirmed cases and over 6.9 million deaths have been reported globally.

**Figure 1. COVID-19 cases reported by WHO Region, and global deaths by 28-day intervals, as of 23 April 2023**

---

**WHO launches new initiative to improve pandemic preparedness**

26 April 2023  News release

To help countries better prepare for future pandemics, WHO launched a new initiative today that provides guidance on integrated planning for responding to any respiratory pathogen such as influenza or coronaviruses.

The new Preparedness and Resilience for Emerging Threats Initiative, or PRET, incorporates the latest tools and approaches for shared learning and collective action established during the COVID-19 pandemic and other recent public health emergencies.

Through the initiative, WHO will use a mode of transmission approach to guide countries in pandemic planning, given that many capacities and capabilities are common among groups of pathogens. PRET answers the call for technical guidance and support for promoting and strengthening integrated preparedness and response, as outlined in World Health Assembly resolutions...

“Preparedness, prevention, and response activities must not be the province of the health sector alone,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Just as health emergencies have impacts across many sectors, so must our preparedness and response efforts span sectors, disciplines and pathogens. It is critical, too, that community engagement and equity are the centre of our efforts, especially for those populations that are marginalized and most at risk.”

...The launch of the initiative is taking place on the last day of meetings with over 120 individuals representing Member States, partners, and the WHO secretariat, to define the path forward for PRET, including the development of a global implementation roadmap for respiratory pathogen pandemic preparedness...
Our World in Data

**Coronavirus (COVID-19) Vaccinations**  [Accessed 29 Apr 2023]

:: 70% of the world population has received at least one dose of a COVID-19 vaccine.

:: **13.38 billion doses** have been administered globally, and **259,282** are now administered each day.

:: 29.7% of people in low-income countries have received at least one dose.

---

**Global Dashboard on COVID-19 Vaccine Equity**

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

**Dashboard on Vaccine Equity** [accessed 29 Apr 2023]: [https://data.undp.org/vaccine-equity/](https://data.undp.org/vaccine-equity/)

See also visualization on **Vaccine Access** and **Vaccine Affordability**
Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/

The ACT-Accelerator Global COVID-19 Access Tracker (GCAT) is a dynamic tool to transparently track progress on access to COVID-19 vaccines, treatments, tests, and PPE.

- **Vaccination**: 1.93 Bn doses delivered by COVAX to date
  - 146 countries with vaccine doses through COVAX

- **Testing**: 176 Mn tests delivered via ACTA to date
  - 184 countries with tests delivered via ACTA

- **Therapeutics**: 313,558 therapeutics allocated to countries that are confirmed

- **Health Workers**: US$ 736 Mn personal protective equipment (PPE) delivered via ACTA to date

Last Update on Mar 30, 2023
Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity

See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research

Overview of donations by top 10 donating countries
Bar chart is ordered by total number of doses pledged. Donut charts are ordered by proportion of pledged donations shipped.

Country Category:
Top 10 Donating Countries

United States: 87% shipped
China: 91% shipped
Germany: 74% shipped
France: 70% shipped
United Kingdom: 69% shipped
Italy: 63% shipped
Australia: 63% shipped
Japan: 63% shipped
Canada: 59% shipped

Remaining: 581,669,508
Total Shipped: 1,630,865,630

U.S.: COVID-19/Vaccines – Announcements/Regulatory Actions/Deployment

HHS News

Last Update on Apr 13, 2023
HHS Awards $147 Million to Support Ending the HIV Epidemic in the United States
April 27, 2023 | News Release

During National Minority Health Month, HHS Organizes First-Ever Nationwide Vaccination Day Event to Bring Health-Related Resources to Black Communities
April 24, 2023 | News Release

FDA
Press Announcements
FDA Roundup: April 28, 2023

...Today, the FDA authorized the following uses of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent for individuals 6 months through 4 years of age with certain types of immunocompromise who have previously received three 0.2 mL doses (Pfizer-BioNTech COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine, Bivalent):
:: a fourth dose administered at least 1 month following the most recent dose;
:: additional doses that may be administered at the discretion of the healthcare provider, taking into consideration the individual's clinical circumstances.

The FDA also revised the Fact Sheets for Pfizer-BioNTech COVID-19 Vaccine, Bivalent, to reflect these changes...

FDA VRBPAC
Advisory Committee Calendar
Vaccines and Related Biological Products Advisory Committee May 18, 2023 Meeting Announcement - 05/18/2023

On May 18, 2023, the committee will meet in open session to discuss and make recommendations on the safety and effectiveness of ABRYSVO (Respiratory Syncytial Virus Vaccine), manufactured by Pfizer Inc., with a requested indication, in Biologics License Application (BLA) 125768 (STN 125768/0), for the prevention of lower respiratory tract disease and severe lower respiratory tract disease caused by RSV in infants from birth through 6 months of age by active immunization of pregnant individuals.

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency [EMA]
News & Press Releases
News: First vaccine to protect older adults from respiratory syncytial virus (RSV) infection (new)
CHMP, Last updated: 26/04/2023

EMA has recommended a marketing authorisation in the European Union (EU) for Arexvy (recombinant, adjuvanted), the first vaccine for active immunisation to protect adults aged 60 years and older against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV)...

News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023 (new)
CHMP, Last updated: 26/04/2023
News: European Immunization Week 2023: Statement by Executive Director Emer Cooke - Routine vaccination matters! Every dose counts to stay protected (new)
Last updated: 24/04/2023

European Immunization Week 2023
Campaign - 24 Apr 2023

ECDC reports: Threat of outbreaks in EU/EEA countries due to persistent gaps in vaccination coverage
News story - 24 Apr 2023

WHO/ECDC report: antimicrobial resistance threatens patient safety in European Region
Press release - 14 Apr 2023

ECDC highlights measures to mitigate possible increase in mpox cases during spring and summer
Press release - 14 Apr 2023

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/

(Africa CDC COVID-19 Vaccine Dashboard (Click to View Entire Population)
China: COVID-19/Vaccines – Announcements/Regulatory Actions/Deployment

National Medical Products Administration – PRC  [to 29 Apr 2023]
http://english.nmpa.gov.cn/

News
COVID-19 situation stable in China despite slight uptick in cases
2023-04-27

Although COVID-19 infections in some regions have increased slightly recently, the possibility of large-scale outbreaks occurring in the short term is small, a disease control official said on Wednesday.

He Qinghua, an official with the National Administration of Disease Prevention and Control, said during a news conference that China's epidemic situation remains stable, but new infections appear to be gradually increasing in some areas.

"This month, the domestic epidemic hit its lowest level since December," he said. "But since the middle of this month, the daily number of new positive cases and their proportion in fever clinic visits have been rising a bit."

He said that newly infected cases are mostly made up of people who have never been infected, who are immunocompromised and whose immunity levels have diminished.

XBB.1.16 has no heightened risk of severe cases, deaths: health expert
2023-04-27

BEIJING -- There have been no new severe hospitalized cases or deaths resulting from the Omicron subvariant XBB.1.16 reported, despite the subvariant's considerable transmission and immune evasion capacities monitored in various countries, a Chinese health expert said on Wednesday.

There is also no indication of heightened severity in XBB.1.16 infections compared to other Omicron subvariants, said Chen Cao, a research fellow at the Chinese Center for Disease Control and Prevention (China CDC), at a press conference held by the State Council joint COVID-19 prevention and control mechanism.

By April 22, China had reported 57 locally transmitted cases of XBB.1.16 and its sub-strains. Based on Chinese monitoring data, the Omicron subvariants BA.5.2 and BF.7 remain predominant among local cases, and cases of XBB and its sub-strains have seen relatively fast growth, Chen said.

The China CDC will watch and analyze future changes of the virus closely, Chen added...

-----

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/

Press Releases
No new digest content identified. Last press release issued 31.08.2022.

-----
Indo: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Government of India – Press Information Bureau
Latest Press Releases
No new digest content identified.

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

- COVID-19 INDIA as on: 29 April 2023, 08:00 IST (GMT+5:30)
  - Active: 51314
  - Discharged: 44356693
  - Deaths: 531508
  (11 Status change since yesterday)

- COVID-19 Vaccination as on: 29 April 2023, 08:00 IST (GMT+5:30)
  - Total Vaccination: 220,66,63,094 (03,875 ↑)

---

**PHEIC**

**Mpox**

Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/situations/monkeypox- outbreak-2022

**Multi-country outbreak of mpox, External situation report#21 - 27 April 2023**

Highlights:
- Since the last situation report published on 13 April 2023, 183 new mpox cases (0.2% increase in total cases) and 14 new related deaths have been reported to WHO.
- Globally, the number of mpox cases reported weekly continues to decline; however, the Western Pacific Region reported an increase in cases (n = 62) in the last three weeks compared to the three weeks prior (n = 46), driven by an outbreak of mpox affecting mainly men in Japan, the Republic of Korea and China, with sustained local transmission...

---

**PHEIC**

**Polio**
**Polio this week as of 26 April 2023 - GPEI**

**Headlines [Selected]**

- **The WHO World Health Assembly (WHA)** is scheduled to take place from 21 to 30 May 2023. While much of the deliberations will focus on the ongoing and evolving COVID-19 situation, the global effort to eradicate polio will also be discussed by Member States. To this effect, the Secretariat has prepared two reports which will inform Member State discussions, namely on polio eradication and on polio transition planning and post-certification.

- WHO would like to thank the Government of the United Kingdom (UK), through its Foreign, Commonwealth and Development Office (FCDO), for its latest contribution of £15 million. This generous support is part of the UK’s multi-year commitment to the global polio eradication effort.

- The Polio Transition Global Vision Stakeholder Forum took place this week, bringing together a wide range of stakeholders to discuss the post-2023 direction of polio transition. During the forum, participants reflected on lessons learned and discussed the way forward, drawing on the findings of the mid-term evaluation of the Strategic Action Plan (2018 – 2023). The outcomes from the forum will be used to develop, by the end of 2023, a new global vision for polio transition, alongside regional action plans and a revised monitoring and evaluation framework.

- **nOPV2 rollout**: Approximately 595 million doses of nOPV2 have been administered across 28 countries under its WHO Emergency Use Listing (EUL) to date. An additional 14 countries have met the requirements for nOPV2 use in the event of an outbreak. Take a look at the [nOPV2 webpage](#) or more information on the vaccine.

**Summary of new polioviruses this week:**
- DR Congo: 15 cVDPV1 cases and 21 cVDPV2 cases
- Madagascar: four cVDPV1 cases

---

**UN OCHA – Current Emergencies**

**Current Corporate Emergencies**

**Afghanistan**

*Editor's Note:*

We observe that OCHA has removed Afghanistan from its listing of “Current Emergencies.” We did not identify any explanation for its removal.

**Somalia**

No new digest content identified.

**Türkiye/Syria Earthquakes**

No new digest content identified.

**Ukraine**

Last Updated: 10 Feb 2023
26 April 2023  Departmental news
WHO launches new initiative to improve pandemic preparedness

25 April 2023  News release
WHO urges increased implementation of recommended tools to combat malaria

24 April 2023  Joint News Release
Global partners announce a new effort – “The Big Catch-up” – to vaccinate millions of children and restore immunization progress lost during the pandemic

WHO Regional Offices
Selected Press Releases, Announcements

WHO African Region
:: 28 April 2023  Tackling hesitancy to boost COVID-19 vaccine uptake in Ghana
:: 24 April 2023  Malaria vaccine plays critical role in turning the tide on malaria in Ghana
:: 24 April 2023  Beyond the numbers: the real-world impact of the malaria vaccine in Kenya

WHO Region of the Americas  PAHO
:: PAHO promotes collaboration between Colombia and Venezuela, and outlines plan to make the Americas free of foot-and-mouth disease
Río de Janeiro, 28 April 2023 (PANAFTOSA- PAHO) – Colombian and Venezuelan authorities have agreed to collaborate in strengthening surveillance against foot-and-mouth disease at their borders, in a joint effort to ensure that Venezuela is certified as free of the disease by the World Organization for Animal Health (OIE). Venezuela will be last...
:: PAHO calls on local governments to join initiatives to promote healthy cities and communities
Washington D.C., 28 April 2023 (PAHO).- The Pan American Health Organization (PAHO) today highlighted the importance of health as a central axis of local agendas and urged mayors to participate in joint initiatives to promote healthy cities and municipalities in the region. "Leaders of cities and municipalities have the opportunity to listen to...
:: Mobile clinics: ensuring equitable access to quality health care in the Northeast
As part of the project "Maintenance of health services in times of Covid-19", implemented since January 2022, the Pan American Health Organization (PAHO) is supporting the North-East Health Directorate in Haiti in the establishment of mobile clinics. The objective of these mobile clinics, deployed in 14 hard-to-reach areas during the month of...
Sustainable Development Goal 3 – Advances, insufficient progress and setbacks prevail
As deadline to 2030 reaches halfway point, countries must accelerate towards meeting health-related targets Santiago, Chile, 26 April 2023 (PAHO)- As the deadline for achieving the United Nations 2030 Agenda for Sustainable Development reaches its halfway mark, progress towards achieving the Sustainable Development Goal relating to health (SDG3)...

#VWA2023: Haiti launches catch-up campaign in "Les Cayes" to improve vaccination coverage
Vaccination Week in the Americas (VWA) was launched this year by Haiti’s Ministry of Health and Population (MSPP) with support from PAHO, in the city of Les Cayes, marking the beginning of a catch-up vaccination campaign in the South Department. This initiative aims to improve immunization coverage in the country, with a particular focus on under...

In Chile, PAHO Director meets President Boric, discusses health sector reform and initiatives to strengthen primary care and mental health
Santiago, Chile, 25 April 2023 (PAHO) – The Director of the Pan American Health Organization (PAHO) Dr. Jarbas Barbosa today met with the President of the Republic of Chile, Gabriel Boric, as well as leaders of the country’s Senate and Chamber of Deputies, where they discussed the current reforms to the country’s health system and initiatives to...

World Malaria Day – Countries must step up efforts to reach vulnerable populations, PAHO Director says
Washington D.C. 25 April 2023 (PAHO) – On World Malaria Day, the Pan American Health Organization (PAHO) Director, Dr. Jarbas Barbosa, calls on countries to intensify malaria elimination efforts among indigenous, mobile and remote communities, the populations disproportionately affected by the disease. Although the total number of malaria cases...

Vaccination Week in the Americas starts: Get up to date, #EachVaccineCounts
Santiago, Chile, 24 April 2023 (PAHO) - The Pan American Health Organization (PAHO) today officially launched Vaccination Week in the Americas, an initiative that aims to mobilize concerted action across the region to boost routine and targeted immunization efforts. Taking place from 22 to 29 April, this year’s Vaccination Week in the Americas (...

WHO South-East Asia Region SEARO
No new digest content identified.

WHO European Region EURO
:: 27 April 2023  News release
Vigilance needed despite encouraging mpox situation: WHO/Europe launches key considerations for control and elimination
:: 27 April 2023  Media release
As Hungary aims to expand its vision of health for all, WHO/Europe and the WHO Country Office in Hungary are partners all the way
:: 26 April 2023  News release
Launch of WHO's first-ever Technical Advisory Group on risk communication, community engagement and infodemic management
:: 26 April 2023  News release
Countries in the European Region stepping up to stop the spread of measles as cases in 2023 already exceed all those in 2022

WHO Western Pacific Region
:: 24 April 2023
Community engagement is key to malaria elimination in Cambodia

Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

28 April 2023 | Measles - Indonesia

27 April 2023 | Diphtheria - Nigeria

27 April 2023 | Meningitis - Nigeria

New WHO Publications
https://www.who.int/publications/i

Selected
28 April 2023

Atlas of mpox lesions: a tool for clinical researchers, 28 April 2023, version 1.0

26 April 2023

2023 emerging technologies and scientific innovations: a global public health perspective — preview of horizon scan results

Overview
This infographic represents a preview of the findings of a global horizon scan of innovations in science and technology that could help solve global health challenges. An expert group scored over 100 innovations for their potential impact and the chance of wide adoption within 5, 5–10 or > 10 years. They also discussed enablers that would facilitate adoption of the innovations.

24 April 2023

Framework and standards for country health information systems, 2nd ed

CDC/ACIP [U.S.] [to 29 Apr 2023]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

Latest News Releases
No new digest content identified.

ACIP Meetings
Next ACIP Meeting: June 21-22
Africa CDC [to 29 Apr 2023]
http://www.africacdc.org/
Press Releases

Africa CDC hosts the Partnerships for African Vaccine Manufacturing (PAVM) Forum

The Partnerships for African Vaccine Manufacturing (PAVM) was established by the African Union (AU), under the Africa CDC, in 2021 to deliver a bold goal: enable the African vaccine manufacturing industry to develop, produce, and supply over 60 percent of the total vaccine doses required on the continent by 2040, up from less than 1 percent. The Continental Framework for Action (FFA) was developed and endorsed during the 40th Ordinary Session of the Executive Council and lays out the key interventions required to enable the development of a sustainable vaccine manufacturing industry in Africa.

The PAVM Forum saw the participation of the African Union Member States, African Manufacturers, National Regulatory Agencies (NRAs), Partners and donors with an objective of providing updates on the Progress achieved under the PAVM Initiative, a thorough review of the eight bold programs, highlight new priorities, outline areas for continued collaboration and support, and interact with member states, manufacturers, funders, and other partners on their priorities...

Articles
Op-Ed: The Big Catch Up: Recovering the Gains Made in Africa through Vaccinations
26 April 2023
Articles
Achieving Sustainable Vaccine Manufacturing: Insights from the 2023 World Vaccine Congress
25 April 2023

China CDC
http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China [to 29 Apr 2023]
http://en.nhc.gov.cn/
News
No new digest content identified.

National Medical Products Administration — PRC [to 29 Apr 2023]
http://english.nmpa.gov.cn/
News
COVID-19 situation stable in China despite slight uptick in cases
2023-04-27
Although COVID-19 infections in some regions have increased slightly recently, the possibility of large-scale outbreaks occurring in the short term is small, a disease control official said on Wednesday.

XBB.1.16 has no heightened risk of severe cases, deaths: health expert
2023-04-27
There have been no new severe hospitalized cases or deaths resulting from the Omicron subvariant XBB.1.16 reported, despite the subvariant's considerable transmission and immune evasion capacities monitored in various countries, a Chinese health expert said on Wednesday.

China CDC Weekly Reports: Current Volume (5)
2023-04-28 / No. 17 WORLD IMMUNIZATION WEEK ISSUE
View PDF of this issue
- Preplanned Studies: Effectiveness of COVID-19 Vaccination Against SARS-CoV-2 Omicron Variant Infection and Symptoms — China, December 2022–February 2023
- Preplanned Studies: Effectiveness of DTaP Against Pertussis in ≤2-Year-Old Children — Linyi Prefecture, Shandong Province, China, 2017–2019
- Preplanned Studies: Coverage of 13-Valent Pneumococcal Conjugate Vaccine Among Children 0–15 Months of Age — 9 Provinces, China, 2019–2021

Organization Announcements
Global Partners Announce a New Effort — “The Big Catch-up” — to Vaccinate Millions of Children and Restore Immunization Progress Lost During the Pandemic

Bill & Melinda Gates Medical Research Institute
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people.

CARB-X published its 2021-2022 annual report today. The report highlights achievements, including CARB-X projects in clinical development, new products on the market, renewed funding commitments, open funding rounds, and Portfolio Acceleration Tools, a series of research projects led by CARB-X to support multiple product developers.

Center for Vaccine Ethics and Policy — GE2P2 Global Foundation
:: Vaccines and Global Health: The Week in Review -22 April 2023
:: Informed Consent: A Monthly Review – April 2023
:: Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest – April 2023
:: Public Consultations Watch :: Global Calls for Input/Public Comment/RFIs - 20 April 2023 – Issue 02

CEPI – Coalition for Epidemic Preparedness Innovations
Latest News
International partnership supports vaccine research to prevent future outbreaks
Canada makes generous pledge of CA$100 million to support CEPI 2.0 five-year plan at launch of CIHR-CEPI Leadership Awards for Excellence in Vaccine Research
26 Apr 2023

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 29 Apr 2023]
https://cioms.ch/
News; Publications; Events

Gender considerations in health research
The meeting report is now available from the CIOMS / GENDRO joint meeting held on 2 February 2023.

CIOMS Glossary of ICH terms and definitions: Version 3 now available
Version 3 of the CIOMS Glossary of ICH terms and definitions is now freely available here. It can also be accessed from the ICH webpage here.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 29 Apr 2023]
https://www.darpa.mil/news
News
No new digest content identified.

Duke Global Health Innovation Center [to 29 Apr 2023]
https://dukeghic.org/
Our Blog
No new digest content identified.

EDCTP [to 29 Apr 2023]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
News
28 April 2023
Professor Moses Bockarie retires as Head of EDCTP Africa Office

Emory Vaccine Center [to 29 Apr 2023]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

World Malaria Day 2023: time to deliver zero malaria
25 April 2023
**European Vaccine Initiative**  [to 29 Apr 2023]
http://www.euvaccine.eu/

*Latest News, Events*

**World Malaria Day 2023**  
On April 25th, we celebrate World Malaria Day and reflect on the progress that has been made in the fight against malaria. This

**Evidence Aid**  [to 29 Apr 2023]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
*Resources [Selected]*
No new digest content identified.

**Fondation Merieux**  [to 29 Apr 2023]
http://www.fondation-merieux.org/

*News, Events*

**Support for Laboratories**  
*C19-HaïtiLab stakeholders met during the project’s first steering committee meeting*
April 25, 2023 - Santo Domingo (Dominican Republic)
Experts from the National Public Health Laboratory (LNSP) of Haiti, the GHESKIO Centers and the Mérieux Foundation, as well as representatives from the Agence française de Développement (AFD), met in Santo Domingo, Dominican Republic, on April 11 and 12, 2023 for workshops and the first steering committee of the C19-HaïtiLab project.

**Gavi**  [to 29 Apr 2023]
https://www.gavi.org/

*News Releases*
27 April 2023  
**Immunisation partners outline ambitious plan to protect millions of girls in lower- and middle-income countries against cervical cancer**

26 April 2023
**Funding disbursed to boost vaccine access in humanitarian and fragile settings**

25 April 2023
**Gavi outlines plans to build sustainable supply of malaria vaccines**

24 April 2023
**South Sudan launches major push on measles vaccination**

24 April 2023
Global partners announce a new effort – “The Big Catch-up” – to vaccinate millions of children and restore immunisation progress lost during the pandemic

**GHIT Fund** [to 29 Apr 2023]
https://www.ghitfund.org/newsroom/press
*Press Releases*
No new digest content identified.

**Global Fund** [to 29 Apr 2023]
*News & Stories*
No new digest content identified.

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 29 Apr 2023]
https://www.glopid-r.org/news/
*News*
No new digest content identified.

**Hilleman Laboratories** [to 29 Apr 2023]
http://www.hilleman-labs.org/
*News & Insights*
No new digest content identified.

**HHMI - Howard Hughes Medical Institute** [to 29 Apr 2023]
https://www.hhmi.org/news
*Press Room*
Research  Apr 27 2023
**Comparing Genes of 240 Mammal Species—and One Famous Dog—Offers New Insights in Biology, Evolutionary History**

In a collection of 11 newly published research papers, genomics further proves its worth by identifying species at risk for extinction, predicting the appearance and performance of a legendary sled dog, and illuminating once-dark corners of evolution and biology.

**Human Vaccines Project** [to 29 Apr 2023]
http://www.humanvaccinesproject.org/
*News*
No new digest content identified.

**IAVI** [to 29 Apr 2023]
https://www.iavi.org/
ICRC  [to 015 Oct 2022]
What's New  [Selected]
Sudan: Ceasefire a potential lifesaver for civilians trapped without food, water, medical care
Geneva (ICRC) – The reported temporary ceasefire in Sudan is a potential lifesaver for civilians who have been trapped in their homes without the ability to access food, clean water, and medical care.
25-04-2023 | News release

INSERM  [to 29 Apr 2023]
https://www.inserm.fr/en/home/
Press Releases
No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

Institut Pasteur  [to 29 Apr 2023]
Press Documents
No new digest content identified.

ISC / International Science Council  [to 29 Apr 2023]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

Blogs

Open science round-up: April 2023
28.04.2023

International Union of Immunological Societies (IUIS)
https://iuis.org/

News/Events [Selected]

2023 International Day of Immunology
Saturday 29th April 2023

The 2023 Day of Immunology theme is ‘Immunology Talks to Public Health.’ IUIS & EFIS invite all international societies to join in the effort to increase global awareness of the importance of immunology and demonstrate how our understanding of human immunology can improve public health.

Read more about the Day of Immunology. REGISTER TODAY!

IVAC [to 29 Apr 2023]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

Updates; Events

World Immunization Week 2023 (Webinar): Game Changers–Vaccine Innovations on the Horizon
When: April 26th, 10:00am-11:30am EDT
Registration: https://jh.zoom.us/webinar/register/WN_t9sySAZwQoiJXZMd4W6z-Q

IVI [to 29 Apr 2023]
http://www.ivi.int/

IVI News & Announcements

IVI begins clinical development of DuoChol oral cholera vaccine

April 28, 2023, SEOUL, Republic of Korea – The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, began clinical development of DuoChol, a new low-cost oral cholera vaccine (OCV) in capsule form. With funding support from the Wellcome Trust and the Swedish government, IVI is preparing to conduct a Phase I clinical trial of the vaccine in Sweden.

Scientists at the University of Gothenburg developed DuoChol, a dry formulation inactivated bacterial whole cell/cholera toxin B subunit OCV with a similar composition as the world’s first WHO-prequalified OCV, DUKORAL®. While DUKORAL® as well as the currently available WHO-prequalified low-cost OCVs, Shanchol™ and Euvichol-Plus®, both developed at IVI, are drinkable vaccines, what sets DuoChol apart is its dry formulation in capsule form. This presentation improves the vaccine’s thermostability, meaning the active ingredients remain stable at higher relative temperatures for a longer duration, while also reducing its weight and volume...
Johns Hopkins Center for Health Security  [to 29 Apr 2023]
https://www.centerforhealthsecurity.org/news/center-news/
Center News  [Selected]
News  [Selected]
No new digest content identified.

MSF/ Médecins Sans Frontières  [to 29 Apr 2023]
http://www.msf.org/
Latest  [Selected Announcements]
Sudan
MSF responds to medical needs, prepares to scale up activities in Sudan
Press Release 26 Apr 2023

National Academy of Medicine  - USA  [to 29 Apr 2023]
https://nam.edu/programs/
News  [Selected]
No new digest content identified.

National Academy of Sciences  - USA  [to 29 Apr 2023]
News
Registration Now Open -- May 24-26 Nobel Prize Summit on Misinformation and Trust in Science
March 19, 2023
Registration is now open for the Nobel Prize Summit 'Truth Trust and Hope' a global conversation on how to stop misinformation from eroding public trust in science. Hosted by NAS and the Nobel Foundation the summit takes place May 24-26 in Washington D.C. and virtually.

National Vaccine Program Office  - U.S. HHS  [to 29 Apr 2023]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
National Vaccine Advisory Committee (NVAC)
June 15-16, 2023 NVAC Meeting

NIH  [to 29 Apr 2023]
http://www.nih.gov/
News Releases
No new digest content identified.

PATH  [to 29 Apr 2023]
https://www.path.org/media-center/
Press Releases
PATH endorses the Digital Public Goods Charter
April 24, 2023
Advancing the use of digital public goods enables countries to build safe, trusted, and inclusive digital public infrastructure at scale, improving outcomes for people.

PATH is pleased to announce its endorsement of the Digital Public Goods Charter (DPG Charter). The multistakeholder DPG Charter campaign aligns and mobilizes diverse stakeholders and initiatives around a compelling shared vision for digital public goods (DPGs). PATH is committed to advancing the use of DPGs in a coordinated effort to deliver solutions that address urgent global challenges such as hunger, pandemics, and climate change.

Co-led by the Digital Impact Alliance (DIAL) and the Digital Public Goods Alliance (DPGA), the DPG Charter will catalyze new ideas and broker new partnerships to drive endorsements and commitments to expand safe, inclusive, and open digital public infrastructure...

Rockefeller Foundation  [to 29 Apr 2023]
https://www.rockefellerfoundation.org/
Selected Reports/Press Releases
No new digest content identified.

Sabin Vaccine Institute  [to 29 Apr 2023]
https://www.sabin.org/press/
Latest News & Press Releases
No new digest content identified.

UNAIDS  [to 29 Apr 2023]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
27 April 2023
Cook Islands’ original path toward equality

UNICEF  [to 29 Apr 2023]
https://www.unicef.org/media/press-releases
Latest press releases, news notes and statements
Press release  27 April 2023
90 per cent of adolescent girls and young women in low-income countries are offline - UNICEF

NEW YORK, 27 April 2023 – Around 90 per cent of adolescent girls and young women do not use the internet in low-income countries, while their male peers are twice as likely to be online, according to a new UNICEF analysis issued on International Day of Girls in ICT. “Closing the digital divide between girls and boys is about more than just having...
Fighting in Sudan rapidly worsening an already dire humanitarian situation for children, warn UNICEF, Save the Children and World Vision

KHARTOUM, 26 April 2023 - As violent clashes in Sudan continue, UNICEF and the child-focused NGOs World Vision and Save the Children are highlighting the danger to children if the current ceasefire is not respected by all parties. Millions of vulnerable girls and boys need immediate humanitarian assistance, and all children need to be protected...

Statement 25 April 2023

Statement by UNICEF Executive Director Catherine Russell on the life of Goodwill Ambassador Harry Belafonte


NEW YORK, 25 April 2023 - "We mourn the loss of Harry Belafonte, one of the world’s greatest actors, singers, producers, and champions of human rights – especially for children. “He served as a UNICEF Goodwill Ambassador for 36 years, where his dedication and generosity of spirit helped set a high standard for the role – meeting with world leaders...

Remarks 25 April 2023

UNICEF Geneva Palais briefing note: Triple impact of cyclone, cholera and flooding threatening survival and well-being of children in Mozambique


MAPUTO, 25 April 2023 – “More than 28,000 cases of cholera have now been recorded in Mozambique. This is ten times the figure reported at the start of February, and more than half of cases are among children. "Case numbers continue to increase, putting children and families at ever more risk. And now, cases of malaria and diarrhoea, other leading...

Press release 24 April 2023

Global partners announce a new effort – “The Big Catch-up” – to vaccinate millions of children and restore immunization progress lost during the pandemic


The pandemic saw essential immunization levels decrease in over 100 countries, leading to rising outbreaks of measles, diphtheria, polio and yellow fever. ‘The Big Catch-up’ is an extended effort to lift vaccination levels among children to at least pre-pandemic levels and endeavours to exceed those. Led by a broad range of national and global...

Unitaid  [to 29 Apr 2023]

https://unitaid.org/

Featured News

26 April 2023

Unitaid welcomes the reconfirmed commitment to health and wellbeing made by Brazil and Portugal

As leaders from the two nations convened at the Brazil-Portugal Summit this week, a memorandum of understanding was signed reiterating the countries’ shared commitments to universal and equitable access to health, and highlighted Unitaid as a key actor in global health...
25 April 2023

**Unitaid issues call for proposals to build effective delivery strategies for new vector control tools**

Recognizing the need for evidence generation and market shaping support, Unitaid is launching a call for proposals to build and catalyse the uptake of an expanded vector control toolbox to fight malaria in two target settings: (1) countries with a high malaria burden, and (2) countries where *Anopheles stephensi* is an emerging threat...

**Vaccine Equity Cooperative [nee Initiative]** [to 29 Apr 2023]
https://vaccineequitycooperative.org/news/

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 29 Apr 2023]
https://www.vaccineacceptance.org/

*Announcements, Blog*

**Sabin Welcomes 7 New Partners into Its 2023-2024 Social and Behavioral Research Grants Program**
April 25, 2023
by: Danielle Countryman, Theresa Sommers, PhD, MPH

The Sabin Vaccine Institute’s Vaccine Acceptance & Demand initiative is proud to announce funding for 7 grant partners awarded through its Social and Behavioral Research Grants Program. Projects will run from March 2023 through August 2024. Interdisciplinary teams will explore drivers of locally-led solutions to support vaccine acceptance, demand, and delivery of childhood routine and adult immunization.

**Vaccine Confidence Project** [to 29 Apr 2023]
http://www.vaccineconfidence.org/

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 29 Apr 2023]
http://www.chop.edu/centers-programs/vaccine-education-center

*No new digest content identified.*

**Wellcome Trust** [to 29 Apr 2023]
https://wellcome.ac.uk/news

*News, Opinion, Reports*

*No new digest content identified.*
ARM [Alliance for Regenerative Medicine] [to 29 Apr 2023]

**ARM Releases Statement on European Commission’s Proposal to Revise EU Pharmaceuticals Legislation**
April 27, 2023 Brussels, BE

The legislative revision is an opportunity for EU policymakers to help address the EU’s stagnation in ATMP clinical trials, company formation, and investment in comparison to the US and China. While the 26 April Commission proposal in some ways improves upon an earlier version, it still falls significantly short of building a sustainable future for the ATMP sector and providing access for EU patients.

BIO [to 29 Apr 2023]

No new digest content identified.
ICBA – International Council of Biotechnology Associations  [to 29 Apr 2023]
https://internationalbiotech.org/news/
News
No new digest content identified.

IFPMA  [to 29 Apr 2023]
https://ifpma.org/
Selected Press Releases, Statements, Publications
Statement  27 Apr 2023
Open letter to G20 Ministers in support of the advancement of the G20 Health Agenda
On 27 April 2023, IFPMA and OPPI issued an open letter to Health Ministers of the G20, highlighting

Statement  24 Apr 2023
24th WHO Expert Committee Meeting on the Selection and Use of Essential Medicines
On 24 April, IFPMA delivered a statement at the 24th WHO Expert Committee Meeting on the Selection and Use of Essential Medicines, held from 24-28 April 2023.

International Alliance of Patients’ Organizations – IAPO  [to 29 Apr 2023]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
Save the date: 10th Global Patients Congress
We are delighted to announce that IAPO’s 10th Global Patients Congress (GPC 2023) - "Innovative patient partnerships at the heart of global health advancement" will be held on 19 - 20 May 2023 at the Maison Internationale des Associations (MIA) in Geneva, Switzerland as a hybrid event.

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest announcements identified

PhRMA  [to 29 Apr 2023]
http://www.phrma.org/
Press Releases
PhRMA Statement on the EU Pharmaceutical Legislation
WASHINGTON, D.C. (April 26, 2023) – Pharmaceutical Research and Manufacturers of America (PhRMA) spokesperson Megan Van Etten issued the following statement on the EU pharmaceutical legislation published today:
“We support the EU commission’s goal of improving the availability of medicines across the European Union. Unfortunately, the proposed overhaul of the EU pharmaceutical legislation could make that goal harder. It shows a profound misunderstanding of how the process of medicine development, approval and access works and will erode the intellectual property system that is essential for the discovery of new treatments and vaccines.”
“Policymakers in the United States and Europe should be working together as strategic allies to bolster innovation and the life sciences sector, rather than ceding ground to foreign competitors through the draft EU legislation and the drug price setting provisions in the Inflation Reduction Act here in the United States.”

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

**AstraZeneca**
*Press Releases* - No new digest announcements identified

**Bharat Biotech**
*Press Releases* - No new digest announcements identified

**BioCubaFarma** – Cuba
*Últimas Noticias* - Website not responding at inquiry

**Biological E**
*News* - No new digest announcements identified

**BioNTech**
*Press Releases* - No new digest announcements identified

**Boehringer**
*Press Releases*
**Boehringer Ingelheim inaugurates largest European development centre for biotechnology**

Ingelheim, Germany, Monday, 04/24/2023 - 13:00
- Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date
- Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account for approx. 50 percent of the company’s research pipeline
- New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists

**CanSinoBIO**
*News* - Website not responding at inquiry

**CIGB**
*Latest News* - Website not responding at inquiry

**Cinnagen**
*Recent News* - No new digest announcements identified

**Clover Biopharmaceuticals** - China
*News* - No new digest announcements identified

**Curevac** [Bayer Ag – Germany]
Gamaleya National Center

Latest News and Events - See Russia above.

GSK

**Press releases for media**

**GSK’s respiratory syncytial virus older adult vaccine candidate gains positive European Medicines Agency CHMP opinion**

27 April 2023

- Positive opinion advances GSK’s goal to provide the first vaccine to help protect older adults from respiratory syncytial virus disease
- Opinion is supported by data showing the vaccine candidate’s exceptional efficacy in older adults, including those with underlying medical conditions
- Decision on EU marketing authorisation expected by July 2023

IMBCAMS, China

*Home* - Website not responding at inquiry

Janssen/JNJ

**Press Releases** - No new digest announcements identified

Merck

**News releases** - No new digest announcements identified

Moderna

**Press Releases**

16 April, 2023 - No new digest announcements identified

Novartis

**News** - No new digest announcements identified

Novavax

**Press Releases** - No new digest announcements identified

Pfizer

**Recent Press Releases**

**U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children**

Thursday, April 27, 2023 - 03:42pm

- PREVNAR 20 offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine, helping to protect against all 20 serotypes contained in the vaccine
- PREVNAR 20 builds on PREVNAR 13® and includes seven additional serotypes shown to be associated with antibiotic resistance, heightened disease severity, invasive potential, and prevalence in pediatric pneumococcal cases.1
- The vaccine further advances Pfizer’s pediatric pneumococcal vaccine portfolio and builds on more than 20 years of Pfizer leadership, legacy and innovation in developing pneumococcal conjugate vaccines

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur
Press Releases - No new digest announcements identified

Serum Institute of India
NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBP
News - No new digest announcements identified

Sinovac
Press Releases - No new digest announcements identified

SK Biosciences
Press Releases - No new digest announcements identified

Takeda
Newsroom - No new digest announcements identified

Vector State Research Centre of Viralogy and Biotechnology
Home - Website not responding [404 error]

WestVac Biopharma
Media - No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]
Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 14, 2023  Issue 1  
https://www.tandfonline.com/toc/uabr21/current  
[Reviewed earlier]

AMA Journal of Ethics
Volume 25, Number 4: E239-304   April 2023  
https://journalofethics.ama-assn.org/issue/clinicians-government  

Meat and Health
As meat production and consumption increase globally, so do incidences of diet-related illnesses, such as coronary artery disease and obesity. Some meat industry practices undermine public and environmental health, both of which clinicians, health professions, health care organizations, and governments are duty-bound to promote. This issue considers the nature and scope of these groups’ obligations to mitigate negative influences of nonhuman animal production and consumption on health in individual, community, domestic, and international spheres.

American Journal of Infection Control
April 2023  Volume 51  Issue 4  p361-480  
http://www.ajicjournal.org/current  
[Reviewed earlier]

American Journal of Preventive Medicine
April 2023  Volume 64  Issue 4  p459-610  
https://www.ajpmonline.org/current  
[Reviewed earlier]

American Journal of Public Health
April 2023  113(4)  
http://ajph.aphapublications.org/toc/ajph/current  
[Reviewed earlier]
**American Journal of Tropical Medicine and Hygiene**
[Reviewed earlier]

**Annals of Internal Medicine**
April 2023  Volume 176, Issue 4
http://annals.org/aim/issue
[Reviewed earlier]

**Artificial Intelligence – An International Journal**
Volume 317  April 2023
[Reviewed earlier]

**BMC Cost Effectiveness and Resource Allocation**
http://resource-allocation.biomedcentral.com/
(Accessed 29 Apr 2023)
[No new digest content identified]

**BMJ Global Health**
April 2023 - Volume 8 - 4
https://gh.bmj.com/content/8/4
[Reviewed earlier]

**BMC Health Services Research**
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 29 Apr 2023)

*Economic burden of acute otitis media, pneumonia, and invasive pneumococcal disease in children in the United States after the introduction of 13-valent pneumococcal conjugate vaccines during 2014–2018*

*Streptococcus pneumoniae remains a leading cause of morbidity, mortality, and healthcare resource utilization (HRU) among children. This study quantified HRU and cost of acute otitis media (AOM), pneumonia, and ...*

Authors: Tianyan Hu, Yan Song, Nicolae Done, Salini Mohanty, Qing Liu, Eric M. Sarpong, Esteban Lemus-Wirtz, James Signorovitch and Thomas Weiss
Citation: BMC Health Services Research 2023 23:398
Content type: Research Published on: 25 April 2023

**BMC Infectious Diseases**
Residual risk of mother-to-child transmission of HBV despite timely Hepatitis B vaccination: a major challenge to eliminate hepatitis B infection in Cambodia

In countries with intermediate or high hepatitis B virus (HBV) endemicity, mother-to-child transmission (MTCT) represents the main route of chronic HBV infection. There is a paucity of information on HBV MTCT...

Authors: Bunthen E, Ko Ko, Rattana Kim, Shintaro Nagashima, Serge Ouoba, Md Razeen Ashraf Hussain, Tomoki Sato, Channarena Chuon, Kanon Abe, Aya Sugiyama, Kazuaki Takahashi, Tomoyuki Akita, Rathavy Tung, Vichit Ork, Md. Shafiqul Hossain, Vonthanak Saphonn...

Citation: BMC Infectious Diseases 2023 23:261
Content type: Research Published on: 26 April 2023

Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis

The two inactivated SARS-CoV-2 vaccines, CoronaVac and BBIBP-CorV, have been widely used to control the COVID-19 pandemic. The influence of multiple factors on inactivated vaccine effectiveness (VE) during lon...

Authors: Shiyao Xu, Jincheng Li, Hongyuan Wang, Fuzhen Wang, Zundong Yin and Zhifeng Wang
Citation: BMC Medicine 2023 21:160
Content type: Research article Published on: 27 April 2023

A scoping review on the decision-making dynamics for accepting or refusing the COVID-19 vaccination among adolescent and youth populations

Global COVID-19 vaccinations rates among youth and adolescent populations prove that there is an opportunity to influence the acceptance for those who are unvaccinated and who are hesitant to receive additiona...

Authors: Roger Blahut, Amanda Flint, Elaina Orlando, Joelle DesChatelets and Asif Khowaja
The current study sought to determine whether public perceptions of other vaccines and diseases than COVID-19 have been impacted by the COVID-19 pandemic. We longitudinally examined whether there had been a ch...

Authors: Anna Soveri, Linda C. Karlsson, Jan Antfolk, Otto Mäki, Linnea Karlsson, Hasse Karlsson, Saara Nolvi, Max Karukivi, Mikael Lindfelt and Stephan Lewandowsky

Citation: BMC Public Health 2023 23:784
Content type: Research Published on: 28 April 2023

BMC Research Notes
http://www.biomedcentral.com/bmcresnotes/content
(Accessed 29 Apr 2023)
[No new digest content identified]

BMJ Evidence-Based Medicine
April 2023 - Volume 28 - 2
https://ebm.bmj.com/content/28/2
[Reviewed earlier]

BMJ Open
January 2023 - Volume 13 - 1
https://bmjopen.bmj.com/content/13/1
[Reviewed earlier]

Bulletin of the Atomic Scientists
March 2023
https://thebulletin.org/magazine/2023-03/
[Reviewed earlier]

Bulletin of the World Health Organization
Volume 101(4); 2023 Apr 1
https://www.ncbi.nlm.nih.gov/pmc/issues/432103/
[Reviewed earlier]

Cell
Apr 27, 2023  Volume 186  Issue 9  p1817-2040
https://www.cell.com/cell/current
[New issue; No digest content identified]
Current Medical Research and Opinion
Volume 39, Issue 4  2023
https://www.tandfonline.com/toc/icmo20/current
[Reviewed earlier]

Current Opinion in Infectious Diseases
April 2023 - Volume 36 - Issue 2
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
Volume 108, Issue 1  December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 23, Issue 1  Pages: 1-87  March 2023
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 33, Issue 3, 2023
http://www.tandfonline.com/toc/cdip20/current
[New issue; No digest content identified]

Development Policy Review
Volume 41, Issue 2  March 2023
https://onlinelibrary.wiley.com/toc/14677679/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 6 - December 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 47, Issue 2  Pages: 245-542  April 2023
https://onlinelibrary.wiley.com/toc/14677717/2023/47/2
EMBO Reports
Volume 24  Issue 4  5 April 2023
https://www.embopress.org/toc/14693178/current
[New issue; No digest content identified]

Emerging Infectious Diseases
Volume 29, Number 3—March 2023
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 42  March 2023
[Reviewed earlier]

Epidemiology and Infection
Volume 151  - 2023
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

:: Conflicts of interest :: Surrogate consent and decisional impairment

Ethics, Medicine and Public Health
Volume 27  April 2023
[Reviewed earlier]

The European Journal of Public Health
Volume 33, Issue 2, April 2023
https://academic.oup.com/eurpub/issue/33/2
[Reviewed earlier]

**Expert Review of Vaccines**
Vol 22 (1) 2023  *Issue In Progress*
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

**Foreign Affairs**
Volume 102, Number 1  January/February 2023
https://www.foreignaffairs.com/issues/2023/102/1
[No new digest content identified]

**Forum for Development Studies**
Volume 50, 2023 - Issue 1
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]

**Genetics in Medicines**
Volume 25, Issue 4  April 2023
[Reviewed earlier]

**Genome Medicine**
https://genomemedicine.biomedcentral.com/articles
[Accessed 29 Apr 2023]
[No new digest content identified]

**Global Health Action**
Volume 16, Issue 1 (2023)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
[Reviewed earlier]

**Global Health: Science and Practice (GHSP)**
Vol. 11, No. 2  April 28, 2023
http://www.ghspjournal.org/content/current
COMMENTS
Novel Approaches to Postnatal Prophylaxis to Eliminate Vertical Transmission of HIV
Despite progress in providing antiretroviral therapy to pregnant women living with HIV, a substantial number of vertical transmissions continue to occur. Novel approaches leveraging modern potent, safe, and well-tolerated antiretroviral drugs are urgently needed.

FIELD ACTION REPORTS
Open Access

Empowering Communities During the COVID-19 Pandemic Through Mothers’ Support Groups: Evidence From a Community Engagement Initiative in Sri Lanka
MSD Wijesinghe, BMI Gunawardana, WMPC Weerasinghe, SASC Karunarathne, VCN Vithana, RMNU Rajapaksha, R Batuwanthudawe and RPP Karunapema

Community empowerment activities conducted by mothers’ support groups in Sri Lanka played a critical role in COVID-19 outbreak control among communities.

A Successful National and Multipartner Approach to Increase Immunization Coverage: The Democratic Republic of Congo Mashako Plan 2018–2020
Paul Lame, Augustin Milabyo, Sylvia Tangney, Gloire O. Mbaka, Christophe Luhata, Jean-Bernard Le Gargasson, Christelle Mputu, Nicole A. Hoff, Sydney Merritt, Dalau M. Nkamba, Djariatou Sow Sall, John Samuel Otomba, Amine El Mourid, Paul Lusamba, Kamel Senouci, Emmanuel Bor, Anne W. Rimoin, Didine Kaba, Guillaume Mwamba and Elisabeth Mukamba

An innovative rapid revitalization strategy strengthened routine immunization systems in the Democratic Republic of the Congo through the engagement of subnational governments and could be applied to other low- and middle-income countries.

Global Legal Monitor – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 29 Apr 2023]

Article

Italy: Constitutional Court Declares Provision on Compensation for Vaccine Injuries Unconstitutional
On February 9, 2023, the Constitutional Court of Italy issued Decision No. 35 (the Decision) declaring the unconstitutionality of article 3, paragraph 1 of Law No. 210 of February 25, 1992, concerning Compensation for Injuries Caused by Irreversible Complications due to Compulsory Vaccinations, Transfusions, and Administration of Blood Products.

Background to the Decision
The Italian Constitutional Court was called to decide on the constitutionality of article 3, paragraph 1 of Law No. 210 in a case pending between the Ministry of Health and the legal representatives of a minor...
In particular, the constitutional question referred to the challenged provision’s restriction of the statutory period for the calculation of compensation for injuries arising from forced vaccination of patients to three years, counted from the moment when the plaintiff became aware of the injury. (No. 1, para. 2.) Hence, the Constitutional Court was requested to decide whether the plaintiff had a right to obtain compensation in its entirety — that is, without the limit of the prior three-year period. (No. 1.1.)

Contributor: Figueroa, Dante
Date: 2023-04-24

Global Public Health
Volume 18, Issue 1 (2023)
http://www.tandfonline.com/toc/rgph20/current
[Reviewed earlier]

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 29 Apr 2023]
[No new digest content identified]

Health and Human Rights
Volume 25, Issue 1, June 2023,
https://www.hhrjournal.org/special-section-global-voices-for-global-equity-expanding-right-to-health-frameworks/

Special Section: Global Voices for Global Justice: Expanding Right to Health Frameworks
The papers in this special section work together to move toward a global social medicine for the 22nd century. They envision a global social medicine that confronts and moves beyond the traditionally colonial, xenophobic, heteronormative, patriarchal, gender-binary-bound, capitalist, and racist histories of the fields of global health and human rights. They seek to instantiate a global social medicine that centers knowledge and experiences from the Global South and works toward social justice and health equity at scale. In this special section, the authors are particularly interested in understanding, challenging, and expanding our perspectives and enactments of the right to health. Unlike neoliberal perspectives on health that often limit their explanatory capacity to how individuals behave in the world, the papers here move beyond the focus on lifestyles and on the phantasmagoria of a sovereign subject with supposedly free agency. Instead, authors work toward critical consciousness that accounts for structural processes—with their inequities and disruptions, as well as their effects on individuals—and how this consciousness can open new horizons for collective transformation and social emancipation in health...

Health Economics, Policy and Law
Volume 18 - Issue 2 - April 2023
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]
Harnessing the Promise of Artificial Intelligence Responsibly

David A. Dorr, MD, MS; Laura Adams, MS; Peter Embí, MD, MS


This Viewpoint discusses the benefits and potential harms of using artificial intelligence (AI) algorithms in medicine and proposes the collaborative creation of a Code of Conduct for AI in Health Care.

AI-Generated Medical Advice—GPT and Beyond

Claudia E. Haupt, JSD, PhD; Mason Marks, MD, JD


This Viewpoint describes medical applications of generative pretrained transformers (GPTs) and related artificial intelligence (AI) technologies and considers whether new forms of regulation are necessary to minimize safety and legal risks to patients and clinicians.
JAMA Health Forum
April 2023, Vol 4, No. 4
https://jamanetwork.com/journals/jama-health-forum/issue
[Reviewed earlier]

JAMA Pediatrics
April 2023, Vol 177, No. 4, Pages 327-441
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

JBI Evidence Synthesis
April 2023 - Volume 21 - Issue 4
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[New issue; No digest content identified]

Journal of Adolescent Health
April 2023 Volume 72  Issue 4  p485-646
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 76 (2023)
https://www.jair.org/index.php/jair
Contents
[Reviewed earlier]

Journal of Community Health
Volume 48, issue 2, April 2023
[Reviewed earlier]

Journal of Current Medical Research and Opinion
...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.
March 8, 2023  Vol 6, No 03 (2023)
https://www.cmro.in/index.php/jcmro/issue/view/65
[Reviewed earlier]
Using Data Science and a Health Equity Lens to Identify Long-COVID Sequelae Among Medically Underserved Populations

Md Nasir, Nicole Cook, Daniel Parras, Sumit Mukherjee, Geralyn Miller, Juan Lavista Ferres, Katherine Chung-Bridges

pp. 521-534

Abstract:
Understanding how post-acute COVID-19 syndrome (PACS or long COVID) manifests among underserved populations, who experienced a disproportionate burden of acute COVID-19, can help providers and policymakers better address this ongoing crisis. To identify clinical sequelae of long COVID among underserved populations treated in the primary care safety net, we conducted a causal impact analysis with electronic health records (EHR) to compare symptoms among community health center patients who tested positive (n=4,091) and negative (n=7,118) for acute COVID-19. We found 18 sequelae with statistical significance and causal dependence among patients who had a visit after
60 days or more following acute COVID-19. These sequelae encompass most organ systems and include breathing abnormalities, malaise and fatigue, and headache. This study adds to current knowledge about how long COVID manifests in a large, underserved population.

Journal of Immigrant and Minority Health
Volume 25, issue 2, April 2023
Contents
[Reviewed earlier]

Journal of Immigrant & Refugee Studies
Volume 21, 2023  Issue 2
https://www.tandfonline.com/toc/wimm20/current
[New issue; No digest content identified]

Journal of Infectious Diseases
Volume 227, Issue 7, 1 April 2023
https://academic.oup.com/jid/issue/227/7
Special Issue: Brokering Development
[New issue; No digest content identified]

Journal of International Development
April 2023 - Volume 35 -  Pages: 383-535  April 2023
https://onlinelibrary.wiley.com/toc/10991328/current
Special Issue: Brokering Development
[Reviewed earlier]

Journal of Medical Ethics
April 2023 - Volume 49 - 4
http://jme.bmj.com/content/current
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews
Volume 10, Issue 1 (2023)
https://institutionalrepository.aah.org/jpcrr/
[Reviewed earlier]

Journal of Pediatrics
March 2023 - Volume 254  p1-106
http://www.jpeds.com/current
[Reviewed earlier]
Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 29 Apr 2023]
[No new digest content identified]

Journal of Public Health Management & Practice
May/June 2023 - Volume 29 - Issue 3
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[Reviewed earlier]

Journal of Public Health Policy
Volume 44, issue 1, March 2023
https://link.springer.com/journal/41271/volumes-and-issues/44-1
Articles
[Reviewed earlier]

Journal of Refugee & Global Health
Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

Journal of the Royal Society – Interface
April 2023  Volume 20  Issue 201
https://royalsocietypublishing.org/toc/rsif/current
[Reviewed earlier]

Journal of Travel Medicine
Volume 30, Issue 2, March 2023
https://academic.oup.com/jtm/issue
[Reviewed earlier]

Journal of Virology
Volume 97   Number 3   March 2023
http://jvi.asm.org/content/current
[Reviewed earlier]

The Lancet
Apr 29, 2023  Volume 401  Number 10386  p1399-1472
https://www.thelancet.com/journals/lancet/issue/current
Editorial
Moving past the COVID-19 emergency in the USA

The Lancet

[Concluding text]

... The USA has been through a traumatic event that should prompt deep reflection and open the way to transformative change. Yet the country seems at risk of falling prey to the cycle of panic and neglect that characterises the response to many health emergencies. The country may move on for now, but unless it faces up to the root causes of the harm COVID-19 did in the USA—health inequities, lack of access to health care, non-communicable diseases, a poisonous political discourse, and mistrust in public health institutions—it will likely find history repeating itself when the next pandemic comes.

Comment

A WHO pandemic instrument: substantive provisions required to address global shortcomings

Roland Alexander Driece, Precious Matsoso, Tovar da Silva Nunes, Ahmed Soliman, Kazuho Taguchi, Viroj Tangcharoensathien

The Lancet Child & Adolescent Health

Apr 2023 Volume 7 Number 4 p223-296, e10
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]

Lancet Digital Health

Apr 2023 Volume 5 Number 4 e174-e247
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]

Lancet Global Health

May 2023 Volume 11 Number 5 e629-e795
https://www.thelancet.com/journals/langlo/issue/current
[Reviewed earlier]

Lancet Infectious Diseases

Apr 2023 Volume 23 Number 4 p381-508, e121-e165
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

Lancet Public Health

Apr 2023 Volume 8 Number 4 e247-e317
https://www.thelancet.com/journals/lanpub/issue/current
[Reviewed earlier]

Lancet Respiratory Medicine
"We wish to suggest a structure for the salt of deoxyribose nucleic acid (D.N.A.)," wrote James Watson and Francis Crick in this journal in 1953 (J. D. Watson and F. H. C. Crick Nature 171, 737–738; 1953). “This structure has novel features which are of considerable biological interest.”

In the 70 years since those famous words were published, researchers have poured huge effort into unravelling those features and harnessing them for medicine. The result is a flourishing understanding of the genetic causes of diseases — and a host of therapies designed to treat them.

Seventy years from now, the world might look back on 2023 as a landmark, as well. This year could see the first authorization of a therapy based on CRISPR–Cas9 gene editing, that involves tweaking the DNA in the body’s non-reproductive (somatic) cells. Gene editing allows scientists — and could soon permit clinicians — to make changes to targeted regions in the genome, potentially ‘correcting’ genes...
that cause disease. Regulators in the United States, the European Union and the United Kingdom are evaluating a therapy that uses this approach to treat sickle-cell disease, and a decision could be made in the next few months.

But even as such advances accrue, researchers are worrying about the future role of gene editing — as well as other, more established forms of gene therapy — in treating disease. Gene therapies currently carry eye-watering price tags, putting them out of the reach of many who need them. High prices could diminish the willingness of government funders to pay for gene-therapy research. And that, in turn, would make it harder for research institutions to continue to attract top talent to the field. Researchers, especially health economists, must work urgently with industry and governments to find a more affordable funding model.

**Million-dollar treatments**

CRISPR–Cas9’s speedy path to the clinic was paved by years of steady advances in forms of gene therapy that use a virus to shuttle genes into cells. Over the past decade, regulators have approved several such gene therapies, for example CAR-T-cell therapies, which engineer immune cells to treat cancer. Hundreds more are in clinical trials.

These therapies typically cost something like US$1 million for a single treatment, and more once the costs of administering them, such as hospital stays and procedures required to isolate and manipulate cells, are factored in. Last year, the US Food and Drug Administration approved the first gene therapy to treat haemophilia B, a genetic disease that impairs blood clotting. The price is $3.5 million per treatment, making the therapy, called Hemgenix, the most expensive drug in the world.

Gene therapies are more costly to develop and produce than are more well-established treatments based on small-molecule drugs. But gene therapies can also carry the hope of a cure, freeing recipients from both long-term reliance on expensive medicines and the risk of hospitalizations. Some have argued that this justifies the high cost: if a therapy can save millions in downstream treatments, the initial outlay would still save money overall. Over time, after all, the costs of more-conventional treatments add up: one study, for example, found that in the United States, the cost of treating a person with sickle-cell anaemia until the age of 64 is $1.7 million (K. M. Johnson et al. Blood Adv. 7, 365–374; 2023).

Even in wealthy countries, health-care systems are ill-equipped to shoulder the high initial costs associated with gene therapies. In 2021, therapeutics developer Bluebird Bio in Somerville, Massachusetts, withdrew plans to market a gene therapy for β-thalassaemia — another blood disorder — in Europe, after failing to reach an agreement with European authorities over the price. It said it would focus its sales efforts on the United States, where there has been comparatively little regulation of drug costs.

But even in the United States, costs matter. US health insurance is often subsidized by employers, and some are already saying that they will probably restrict their coverage of gene therapies in the next year, says Steven Pearson, president of the Institute for Clinical and Economic Review, a health-economics think tank in Boston, Massachusetts.

Low- and middle-income countries, meanwhile, are left entirely in the lurch. This is especially painful given that some of the diseases under consideration, such as β-thalassaemia and sickle-cell disease, are more common in poorer parts of the world than in wealthy nations. In some sub-Saharan regions,
for example, it is estimated that about 2% of children are born with sickle-cell disease. This is likely to be an underestimate, given how little screening is taking place.

Improving access
It is too soon to know how much the CRISPR–Cas9 treatment for sickle-cell disease would cost; neither of its developers, Vertex Pharmaceuticals in Boston, Massachusetts, or CRISPR Therapeutics in Cambridge, Massachusetts, have disclosed what they will charge. But researchers are bracing themselves for the price tag to come.

At the Third International Summit on Human Genome Editing, held in London in March, much of the discussion centred on making gene-editing therapies accessible, particularly to low- and middle-income countries. The focus was on technological approaches to streamline the production and testing of such treatments. The sickle-cell treatment, for example, requires clinicians to isolate and edit blood-forming stem cells, destroy those that remain in the body, and then reinfuse the edited cells. Converting this to a genome-editing procedure that could be performed directly in the body rather than in isolated cells could make the treatment cheaper and more accessible.

Another appealing approach is to develop gene-therapy platforms that have already been confirmed to be safe and effective. Gene-therapy developers could then just swap in a gene that targets the chosen disease, without the gamut of tests of safety and efficacy that are required when starting from scratch.

But technological solutions such as these will go only so far. US drug pricing has little to do with how much it costs to produce a therapy, says Pearson, because companies can charge as much as the market will bear. How much that price will drop in other countries could be limited by intellectual property rights and hindered by the complexities of making generic copies of biological drugs such as gene therapies. Some academic centres are trying to develop and deploy gene therapies without relying on pharmaceutical companies, but it is unclear how far such efforts can stretch without the financial resources and regulatory expertise found in industry.

In addition to pricing, gene-therapy technologies are mired in debates around regulation and intellectual property. How each of these plays out will determine how far researchers can go in capitalizing on Watson and Crick’s initial discovery. It’s important that scientists have an active role in these debates, and that they push such discussions to the fore sooner rather than later.

Nature Biotechnology
Volume 41 Issue 4, April 2023
https://www.nature.com/nbt/volumes/41/issues/4
Editorial 05 Apr 2023
Data sharing in the age of deep learning
How can we protect personal information and the integrity of artificial intelligence models when sharing data?

Nature Communications
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 29 Apr 2023)
[No new digest content identified]
Perspective

**Fundamentals of Health Law: Access to Biomedical Innovation — Inside the Legal Labyrinth**

A.K. Rai
AI in Medicine: Advances in Artificial Intelligence for Infectious Disease Surveillance
J.S. Brownstein, B. Rader, C.M. Astley, and H. Tian

Editorials
Genomics in Clinical Practice
J. E. Posey and J.R. Lupski

npj Vaccines
https://www.nature.com/npjvaccines/
[Accessed 29 Apr 2023]
[No new digest content identified]

Pediatrics
Volume 151, Issue 4  April 2023
https://publications.aap.org/pediatrics/issue/151/4
[Reviewed earlier]

PharmacoEconomics
Volume 41, issue 5, May 2023
Systematic Review
Accounting for Adverse Events Following Immunization in Economic Evaluation:
Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus,
Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella
Authors: Kris Doggen, Albert Jan van Hoek, Jeroen Luyten
Published: 21 February 2023
Pages: 481 - 497
   Economic evaluations of vaccines should accurately represent all relevant economic and health consequences of vaccination, including losses due to adverse events following immunization (AEFI). We investigated to what extent economic evaluations of pediatric vaccines account for AEFI, which methods are used to do so and whether inclusion of AEFI is associated with study characteristics and the vaccine’s safety profile.

PLoS Biology
https://journals.plos.org/plosbiology/
The future is bright, the future is biotechnology
Richard Hodge, on behalf of the PLOS Biology staff editors
Editorial | published 28 Apr 2023 PLOS Biology
https://doi.org/10.1371/journal.pbio.3002135

Synthetic biology: Learning the way toward high-precision biological design
Shohei Kitano, Ciai Lin, Jee Loon Foo, Matthew Wook Chang
Perspective | published 26 Apr 2023 PLOS Biology
Rethinking global digital health and AI-for-health innovation challenges
Andrew Farlow, Alexander Hoffmann, Girmaw Abebe Tadesse, Deogratias Mzurikwao, Rob Beyer, Darlington Akogo, Eva Weicken, Tafadzwa Matika, MaryJane Ijeomà Nweje, Watu Wamae, Sako Arts, Thomas Wiegand, Colin Bennett, Maha R. Farhat, Matthias I. Gröschel
Review | published 28 Apr 2023 PLOS Global Public Health
https://doi.org/10.1371/journal.pgph.0001844

Best practices in the African Medicines Regulatory Harmonization initiative: Perspectives of regulators and medicines manufacturers
Margareth Ndomondo-Sigonda, Samvel Azatyan, Petra Doerr, Collins Agaba, Kristin N. Harper
Research Article | published 26 Apr 2023 PLOS Global Public Health
https://doi.org/10.1371/journal.pgph.0001651

Reimagining the journey to recovery: The COVID-19 pandemic and global mental health
Vikram Patel, Daisy Fancourt, Toshi A. Furukawa, Lola Kola
Editorial | published 24 Apr 2023 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1004224

Digital health in fragile states in the Middle East and North Africa (MENA) region: A scoping review of the literature
Understanding COVID-19 vaccine hesitancy in Malaysia: Public perception, knowledge, and acceptance
Nurul Azmawati Mohamed, Hana Maizuliana Solehan, Mohd Dzulkhairi Mohd Rani, Muslimah Ithnin, Mahalecthumy Arujanan
Research Article | published 27 Apr 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0284973

Understanding vaccine hesitancy with PCV13 in children: Results of a survey in Shanghai, China
Yi-hong Ni, Zhen-hui Xu, Jing Wang
Research Article | published 27 Apr 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0284810

COVID-19 stigmatization after the development of effective vaccines: Vaccination behavior, attitudes, and news sources
Don C. Des Jarlais, Sarah Lieff, Margaux Grivel, Gabriella Meltzer, Jasmin Choi, Chenziheng Allen Weng, Jonathan P. Feelemyer, Virginia W. Chang, Lawrence Yang
Research Article | published 27 Apr 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0283467

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 29 Apr 2023]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States
April 25, 2023  vol. 120  no. 17
https://www.pnas.org/toc/pnas/120/17
[New issue; No digest content identified]

PNAS Nexus
Volume 2, Issue 4, April 2023
https://academic.oup.com/pnasnexus/issue
Psychological and Cognitive Sciences
Visual policy narrative messaging improves COVID-19 vaccine uptake
Elizabeth A Shanahan and others
PNAS Nexus, Volume 2, Issue 4, April 2023, pgad080,
https://doi.org/10.1093/pnasnexus/pgad080
Prehospital & Disaster Medicine
Volume 38 - Issue 2 - April 2023
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 169  April 2023
Research article  Open access
Effectiveness and feasibility of three types of parent reminders to increase adolescent human papillomavirus (HPV) vaccination
Beth A. Glenn, Catherine M. Crespi, Alison K. Herrmann, Narissa J. Nonzee, ... Roshan Bastani
Article 107448

Research article  Abstract only
Characterizing U.S. mothers with high human papillomavirus vaccine intent yet unvaccinated adolescents
Tuhina Srivastava, Katharine J. Head, Sean M. O'Dell, Kristen A. Feemster, ... Melanie L. Kornides
Article 107472

Proceedings of the Royal Society B
26 April 2023  Volume 290  Issue 1997
https://royalsocietypublishing.org/toc/rspb/current
[New issue; No digest content identified]

Public Health
Volume 217  Pages 1-218 (April 2023)
[Reviewed earlier]

Public Health Ethics
Volume 15, Issue 3, November 2022
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 138 Issue 2, March/April 2023
https://journals.sagepub.com/toc/phrg/138/2
[Reviewed earlier]

Qualitative Health Research
Volume 33 Issue 5, April 2023
Research Ethics
Volume 19 Issue 2, April 2023
[Reviewed earlier]

Reproductive Health
[Accessed 29 Apr 2023]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en

Selected Articles
28 Apr 2023
**A framework to assess potential health system resilience using fuzzy logic**
Original research | English |

28 Apr 2023
**Public, private, and public-private partnerships to implement One Health as an action to address antimicrobial resistance in Colombia**
Opinion and analysis | Spanish |

24 Apr 2023
**Synthesis of evidence and recommendations: guideline for the treatment of leishmaniasis in the Region of the Americas**
Special report | Spanish |

24 Apr 2023
**The Pan American Health Organization’s Revolving Fund for access to vaccines: 43 years responding to the regional immunization program**
Special report | Spanish |

24 Apr 2023
**Milestones on the road to health equity at the Pan American Health Organization**
Special report | Spanish |

24 Apr 2023
**Noncommunicable diseases in the Americas: a review of the Pan American Health Organization’s 25-year program of work**
Special report | English |
Mammals are one of the most diverse classes of animals, ranging both in size, across many orders of magnitude, and in shape—nearly to the limit of one’s imagination. Understanding when, how, and under what selective pressures this variation has developed has been of interest since the dawn of science.

Genomics can provide insight into the evolution and generation of important genetic variation and morphological traits. Further, because humans are also mammals, understanding genetic variation across species can provide insight into not just our own evolutionary history but also our health. Genes that are conserved across many species may indicate those that are essential for normal function and thus may lead to disease when altered. Alternatively, genes that are distinctive to specific groups or species may be the result of selection for particular adaptive traits. In this collection of papers, the genomes of 240 mammals from across the mammalian tree of life are used to perform a variety of investigations, from identifying adaptive traits and morphology in the famous sled dog Balto and revealing evolutionary innovation across mammals to narrowing in on potential genes related to disease in humans.

Approaches used to produce and analyze this large number of genomes will pave the way for similar large-scale analyses of other taxonomic groups. The Zoonomia project heralds a new era in which the joint production of genomes from hundreds of species will open the door to new ways of understanding mammals, mammalian evolution, and ourselves.
A global analysis of the effectiveness of policy responses to COVID-19
Kwadwo Agyapon-Ntrah & Patrick E. McSharry

volume 13, Article number: 5629 (2023)   Open Access
Published: 06 April 2023

Abstract
Governments implemented many non-pharmaceutical interventions (NPIs) to suppress the spread of COVID-19 with varying results. In this paper, country-level daily time series from Our World in Data facilitates a global analysis of the propagation of the virus, policy responses and human mobility patterns. High death counts and mortality ratios influence policy compliance levels. Evidence of long-term fatigue was found with compliance dropping from over 85% in the first half of 2020 to less than 40% at the start of 2021, driven by factors such as economic necessity and optimism coinciding with vaccine effectiveness. NPIs ranged from facial coverings to restrictions on mobility, and these are compared using an empirical assessment of their impact on the growth rate of case numbers. Masks are the most cost-effective NPI currently available, delivering four times more impact than school closures, and approximately double that of other mobility restrictions. Gathering restrictions were the second most effective. International travel controls and public information campaigns had negligible effects. Literacy rates and income support played key roles in maintaining compliance. A 10% increase in literacy rate was associated with a 3.2% increase in compliance, while income support of greater than half of previous earnings increased compliance by 4.8%.
Global trends in research related to the links between microbiota and antibiotics: a visualization study
Sa’ed H. Zyoud, Muna Shakhshir, Samah W. Al-Jabi
Article 27 Apr 2023

Abstract
The scientific community widely acknowledges that the gut microbiota plays a critical role in maintaining host health and can be altered by a range of factors, such as antibiotic use, diet, stress, and infections. Therefore, this study utilized bibliometric analysis to thoroughly investigate research trends in the microbiota and antibiotics. Scopus was used to extract papers linked to microbiota and antibiotics published between 2002 and 2021, and both Microsoft Excel and VOSviewer were used to conduct the analysis of the data. A total of 2,816 publications discussed the connection between the microbiota and antibiotics. Growth occurred in two stages: the first (2002–2015) was characterized by fairly slow publication production, while the second (2016–2021) saw a rapid increase in publishing progress. The United States has the most publications, 654, representing 23.22% of the total. China came second with 372 publications (13.21%), followed by the United Kingdom with 161 publications (5.72%) and India with 157 publications (5.58%). In addition, publications on ‘altered intestinal microbiota composition with antibiotic treatment’ were introduced after 2017, while ‘gut microbiota and antimicrobial resistance’ and ‘probiotics as an alternative antimicrobial therapy’ were introduced before 2017. Based on these results, this study provides an in-depth look at key moments in the history of microbiota and antibiotic research, as well as possible directions for future research in different areas of microbiota and antibiotic research. Therefore, it is suggested that more attention should be given to the latest promising hotspots, such as how antibiotic treatment changes the composition of the gut microbiota.
**Tropical Medicine & International Health**
Volume 28, Issue 4  Pages: i-iv, 247-342  April 2023
[Reviewed earlier]

**Vaccine**
Volume 41, Issue 15  Pages 2427-2630 (6 April 2023)
https://www.sciencedirect.com/journal/vaccine/vol/41/issue/15

**Selected Content**

**Research article  Abstract only**

**Evaluation of the effectiveness of maternal immunization against pertussis in Alberta using agent-based modeling: A Canadian immunization research network study**
Karsten Hempel, Wade McDonald, Nathaniel D. Osgood, David Fisman, ... Alexander Doroshenko
Pages 2430-2438

**Research article  Full text access**

**COVID-19 vaccine hesitancy among people living with HIV in a low-resource setting: A multi-center study of prevalence, correlates and reasons**
Sahabi Kabir Sulaiman, Muhammad Sale Musa, Fatimah Isma’il Tsiga-Ahmed, Farouq Muhammad Dayyab, ... Saeed Sulaiman
Pages 2476-2484

**Research article  Full text access**

**Uptake of Mpox vaccination among transgender people and gay, bisexual and other men who have sex with men among sexually-transmitted infection clinic clients in Vancouver, British Columbia**
Mark Gilbert, Aidan Ablona, Hsiu-Ju Chang, Troy Grennan, ... Gina Ogilvie
Pages 2485-2494

**Research article  Full text access**

**Willingness to vaccinate children against COVID-19 declined during the pandemic**
R.D. Goldman, R.J. Hart, J.N. Bone, M. Seiler, ... S.H. Baumer-Mouradian
Pages 2495-2502

**Vaccines**
https://www.mdpi.com/journal/vaccines
[Accessed 29 Apr 2023]

**Latest Articles**
[No new digest content identified]

**Value in Health**
April 2023  Volume 26  Issue 4  p441-616
https://www.valueinhealthjournal.com/current
[Reviewed earlier]
Pre-Print Servers

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 29 Apr 2023]
Selected Research
Impact of the COVID-19 pandemic on women’s contraceptive use: a mixed-methods study in South Africa and Zambia [version 1; peer review: awaiting peer review]
Rebecca L. Callahan, Alice F. Cartwright, Mags Beksinska, Margaret Kasaro, Jennifer H. Tang, Cecilia Milford, Christina Wong, Marissa Velarde, Virginia Maphumulo, Maria Fawzy, Manze Chinyama, Esther Chabu, Mayaba Mudenda, Jennifer Smit
Peer Reviewers Invited
Funders
Swedish International Development Cooperation Agency
United States Agency for International Development
South African Medical Research Council
United Nations Population Fund
PUBLISHED 27 Apr 2023

medRxiv
https://www.medrxiv.org/content/about-medrxiv
[Accessed 29 Apr 2023]
[Filter: All articles]
Selected Research
Planning ahead for research participation: survey of public and professional stakeholders views about the acceptability and feasibility of advance research planning
Victoria Shepherd, Kerenza Hood, Fiona Wood
medRxiv 2023.04.25.23289103; doi: https://doi.org/10.1101/2023.04.25.23289103

The Brazilian COVID-19 vaccination campaign: A modelling analysis of socio-demographic factors on uptake
Assessing Willingness to receive COVID-19 Vaccines, associated factors and reasons for hesitancy among persons aged 13-80 years in Central Uganda. A population-based surveillance Cohort
Alex Daama, Naziru Rashid, Kasango Asani, Grace Kigozi Nalwoga, Fred Nalugoda, Robert Bulamba, Emmanuel Kyasanku, Gertrude Nakigozi, Godfrey Kigozi, Joseph Kagaayi, Stephen Mugamba

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7_CLife%20Sciences
[Accessed 29 Apr 2023]
[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. If this continues, we may decide to no longer monitor this resource.

Guidance for Researchers and Peer-reviewers on the Ethical Use of Large Language Models (LLM) in Scientific Research Workflows
Ryan Watkins
Last edited: Apr 22, 2023 UTC
Abstract
For researchers interested in exploring the exciting applications of Large Language Models (LLMs) in their scientific investigations, there is currently limited guidance and few norms for them to consult. Similarly, those providing peer-reviews on research articles where LLMs were used are without conventions or standards to apply or guidelines to follow. This situation is understandable given the rapid and recent development of LLMs (such as OpenAI's ChatGPT) that are capable of valuable contributions to research workflows. Nevertheless, now is the time to begin the development of norms, conventions, and standards that can be applied by researchers and peer-reviewers. This editorial proposes an initial framework and set of guiding considerations, which will hopefully inspire further dialogue and research on applying AI ethics to the use of LLMs in the workflows of scientific research.
the complex nature of invisibility and its interconnectedness with social, political and economic issues and trends, we argue that while local and targeted interventions might provide relief and comfort locally, they will not be able to solve the underlying causes of invisibility. Moving forward, we argue that in dealing with an intersectional issue such as invisibility, twenty-first century global health bioethics could pursue a more ‘disturbing’ framework, challenging the narrow comforting solutions and sociomaterial inequalities of the sociopolitical status quo. We highlight that comforting and disturbing bioethical frameworks should not be considered as opposing sides, but as two approaches working in tandem in order to achieve the internationally set global health milestones of providing better health and wellbeing for everyone. In doing so, we call for taking seriously insights from sociology, anthropology, postcolonial studies, history, feminist studies and other styles of critical reasoning that have long been disturbing the grand assumptions about people and their conditions, and, practically, to rediscover the ethos of the WHO Alma Ata Declaration, calling for cooperation and support beyond the narrow market logic that dominates the landscape of contemporary global health.

* * *

**Think Tanks**

**Brookings**  [to 29 Apr 2023]
http://www.brookings.edu/
*Latest Research [Selected]*
*No new digest content identified.*

**Center for Global Development**  [to 29 Apr 2023]
https://www.cgdev.org/
*All Research [Selected]*
*No new digest content identified.*

**Chatham House**  [to 29 Apr 2023]
https://www.chathamhouse.org/
*Selected Analysis, Comment, Events*
*No new digest content identified.*

**Kaiser Family Foundation**  [to 29 Apr 2023]
https://www.kff.org/search/?post_type=press-release
*Newsroom*
**During the COVID-19 Pandemic, People of Color Were More Likely to Die at Younger Ages**
April 24, 2023 News Release
The Nation Overall Also Experienced Higher Rates of Premature Deaths than Peer Countries During the COVID-19 pandemic, people of color on average died at younger ages than White adults, resulting in substantial racial disparities in premature death and years of life lost, a new analysis finds. The analysis examines the...

**McKinsey Global Institute**
https://www.mckinsey.com/mgi/overview
Latest Research
No new digest content identified.

**ODI [Overseas Development Institute]** [to 29 Apr 2023]
Latest Publications [Selected]
No new digest content identified.

**Pew Research Center** [to 29 Apr 2023]
https://www.pewresearch.org/
Latest Publications [Selected]
No new digest content identified.

**Rand** [to 29 Apr 2023]
https://www.rand.org/pubs.html
Published Research [Selected]
Journal Article
**Vaccinations Against COVID-19 May Have Averted Up To 140,000 Deaths In The United States**
As of May 9, 2021, reductions in COVID-19 deaths associated with vaccines had translated to value of statistical life benefit ranging between $625 billion and $1.4 trillion.
Apr 27, 2023
Sumedha Gupta, Jonathan H. Cantor, Kosali Ilayperuma Simon, Ana I. Bento, Coady Wing, Christopher M. Whaley

**Urban Institute** [to 29 Apr 2023]
https://www.urban.org/publications
New Research Publications - Selected

**World Economic Forum** [to 29 Apr 2023]
https://agenda.weforum.org/news/
Media
No new digest content identified.
Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.